In honour of Prostate Cancer Awareness Month, Dr. Phil Cohen, MD, FRCP(C), ABNM, joined our Coast to Coast Prostate Cancer Support Group Meeting as part of our Prostate Cancer Awareness Speaker Series. --- About Dr. Cohen: Dr. Philip Cohen is the Division Head of Nuclear Medicine at Lions Gate Hospital in Vancouver, Canada. He is the past chairman of the Diagnostic Accreditation Subcommittee for Nuclear Medicine of the British Columbia (B.C.) Medical Association and the B.C. College of Physicians, Member-at-Large of the Canadian Association of Nuclear Medicine, and Clinical Professor at the University of B.C. Dr Cohan has numerous publications and is a member of the editorial board of the Iranian Journal of Nuclear Medicine. He is a Fellow of the Royal College of Physicians and Surgeons of Canada in Nuclear Medicine, and also of the American Board of Nuclear Medicine. Dr. Cohen is a pioneer in Nuclear Medicine in Canada and in the usage of 3-D imaging techniques to improve diagnosis of bone disease and injury in collaboration with the Medical Imaging Research Group at University of British Columbia. Dr Cohen has been involved in clinical research trials of new radiopharmaceuticals. To that effect, he was the first recipient of a research grant from the Lions Gate Hospital Foundation, one of several peer-reviewed awards that would follow. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

In honour of Prostate Cancer Awareness Month, Dr. Abby Collier spoke at our Prostate Cancer Awareness Month 2021 Speaker Series. Prostate cancer (PCa) affects Canadian citizens widely and is one of the most common cancers diagnosed in either genders. As time has progressed we have become better at diagnosing and treating PCa. However scientific and medical efforts continue to push the boundaries of diagnosis and therapy. In this presentation Dr Collier will present some of the newly approved diagnostics and therapeutics for PCa, including providing a broad overview of how these fields are developing from a research and clinical trial perspective. About Dr. Collier: Originally from New Zealand, Dr. Collier holds both a BSc and PhD in pharmacology from the University of Auckland. After a postdoctoral fellowship with Professor Chris Pritsos at the University of Nevada, Dr. Collier was an assistant professor, then associate professor at the University of Hawaii Medical School. A member of the Faculty of Pharmaceutical Sciences at UBC since 2013, Dr. Collier is professor of Drug Metabolism and Pharmacokinetics, teaches pharmacology to undergraduate, graduate, pharmacy and medical students, maintains an active and well-funded research lab and directs the new undergraduate BPSc degree program. Dr. Collier's sub-specialty is drug metabolism and pharmacokinetics. She is the winner of the 2021 Center for Alternatives to Animal Testing (CAAT) Award (biennial, world-wide) in recognition of her scientific research leading the field in modeling and simulation “to reduce, refine and replace animal use”. She uses a combination of laboratory work and computer modeling to improve drug/chemical safety and efficacy. Along with her collaborators, she also performs research and publishes regularly in the fields of human and environmental toxicology and endocrinology, including prostate cancer. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's (formerly Prostate Cancer Foundation BC) Nationwide Active Surveillance Support Group meeting held over Zoom. --- In honour of Prostate Cancer Awareness Month, Dr. Laurence Klotz, MD, FCRPC, and pioneer of Active Surveillance will be joining us for our September meeting. Don't miss out on this opportunity to chat with Canada's leading expert in Active Surveillance. This new nationwide Active Surveillance support group aims to bring together prostate cancer patients and advocates who will empower men newly diagnosed with low-risk and intermediate prostate cancer by providing them with the latest information to help them make informed decisions with their physicians regarding approaches to active surveillance. Go to prostatecanada.ca to find out more. --- About Laurence Klotz, CM, MD, FRCSC: Dr. Klotz is a widely published uro-oncologist (504 peer review publications, 6 books). His basic research interests have included research in the role of micronutrients and diet in prostate cancer prevention, and translational research in biomarkers and imaging. His research lab has been active for 30 years, producing several patents and a biotech company. His clinical research interests have been in the areas of active surveillance, image guided therapy, molecular biomarkers, and androgen receptor targeted therapy. He has led numerous randomized trials in prostate cancer. Active surveillance was a concept pioneered under Dr. Klotz’s leadership. He led the team at Sunnybrook who was the first to implement an approach to patients with low risk prostate cancer based on conservative management, with selective intervention for those patients who were diagnosed as higher risk over time. He coined the term ‘active surveillance’, and was responsible for promoting its acceptance by urological and radiation oncology communities worldwide. His drive to reduce the overtreatment, morbidity, and mortality of prostate cancer has led to over a hundred papers on this subject alone and numerous national and international invitations as a guest lecturer and visiting professor. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's (formerly Prostate Cancer Foundation BC) Coast to Coast Nationwide Support Group meeting held over Zoom. --- Dr. Michael Fraser is Director, Implementation at Movember Canada. Dr. Fraser obtained his Ph.D. degree from the University of Ottawa in 2006 and completed post-doctoral training in radiation medicine and prostate cancer genomics at the Princess Margaret Cancer Centre. Prior to joining Movember, Dr. Fraser was Scientific Director of the Canadian Prostate Cancer Genome Network (CPC-GENE), Staff Scientist at the Princess Margaret Cancer Centre, and Director of Prostate Cancer Research at the Ontario Institute for Cancer Research. In 2017, Dr. Fraser and his team identified a molecular ‘signature’ that accurately predicts an individual man’s risk of developing metastatic prostate cancer after radiotherapy or surgery. Dr. Fraser also studies prostate cancers that are inherited within families to determine why some of these cancers are very aggressive. Dr. Fraser has authored 42 research papers on prostate cancer genomics and is the holder of multiple patents related to biomarkers for improving treatment of localized prostate cancer. An avid photographer and tennis player, Dr. Fraser lives in Toronto with his wife and two children. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.